NASDAQ
1.10USD
0.00 (0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
136.9M
P/E
—
EPS
—
Beta
0.98
52W range
1-3.06
Day range
1.07–1.13
Open
1.11
Prev close
1.10
Volume
1.6M
Avg volume
1.6M
Dividend
0.00
IPO
2019-05-09
https://seekingalpha.com/article/4937577-milestone-pharmaceuticals-stock-reiterating-sell-as-the-losses-compound · 8/18/2026-1.00
https://www.marketbeat.com/instant-alerts/milestone-pharmaceuticals-q2-earnings-call-highlights-2026-08-12/ · 8/12/2026+0.80
https://seekingalpha.com/article/4913435-milestone-pharmaceuticals-here-comes-the-revenue-ramp · 6/9/2026+0.80
https://seekingalpha.com/article/4853384-milestone-pharmaceuticals-inc-mist-discusses-fda-approval-and-clinical-insights-for-cardamyst · 12/15/2025+0.80
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
